The path to personalised medicine in COPD

Abstract Our understanding of chronic obstructive pulmonary disease (COPD) has changed dramatically over the past two decades. We have moved from an airflow limitation-centric view to the realisation that COPD is a complex and heterogeneous disease, which leads inevitably to the need for personalising the assessment and treatment of patients with COPD. This review provides a brief perspective of the extraordinary transition that the COPD field has experienced in the last two decades, and speculates on how it should/can move forward in the near future in order to really achieve the goal of personalising COPD medicine in the clinic.

[1]  B. Grant,et al.  Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. , 2014, Annals of the American Thoracic Society.

[2]  L. Edwards,et al.  Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality , 2014, Thorax.

[3]  S. Sethi.  Chronic obstructive pulmonary disease and infection. Disruption of the microbiome? , 2014, Annals of the American Thoracic Society.

[4]  J. Kiley,et al.  The lung microbiome. A new frontier in pulmonary medicine. , 2014, Annals of the American Thoracic Society.

[5]  Richard J Martin,et al.  The lung microbiome. A new frontier in pulmonary medicine: introduction and perspective. , 2014, Annals of the American Thoracic Society.

[6]  E. Israel,et al.  Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. , 2014, The Lancet. Respiratory medicine.

[7]  L. Edwards,et al.  Coronary artery calci fi cation is increased in patients with COPD and associated with increased morbidity and mortality , 2014 .

[8]  F. Martinez,et al.  Significance of the microbiome in chronic obstructive pulmonary disease. , 2013, Annals of the American Thoracic Society.

[9]  A. Agustí.  Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? , 2013, Annals of the American Thoracic Society.

[10]  F. Martinez,et al.  The lung microbiome and viral-induced exacerbations of chronic obstructive pulmonary disease: new observations, novel approaches. , 2013, American journal of respiratory and critical care medicine.

[11]  S. Johnston,et al.  Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[12]  A. Agustí,et al.  Cardiovascular comorbidity in COPD: systematic literature review. , 2013, Chest.

[13]  L. Edwards,et al.  Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. , 2013, Respiratory medicine.

[14]  I. Pavord,et al.  Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? , 2013, Thorax.

[15]  B. Nordestgaard,et al.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.

[16]  Harry J de Koning,et al.  Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening , 2013, Respiratory Research.

[17]  D. Aberle,et al.  Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.

[18]  What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. , 2013, American journal of respiratory and critical care medicine.

[19]  S. Hurd,et al.  FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts , 2013, European Respiratory Journal.

[20]  B. Celli,et al.  Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. , 2013, Respiratory medicine.

[21]  M. Martínez-García,et al.  Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[22]  Courtney Crim,et al.  The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. , 2013, The Lancet. Respiratory medicine.

[23]  L. Wood,et al.  Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? , 2013, Thorax.

[24]  D. Price,et al.  GOLD COPD categories are not fit for purpose in primary care. , 2013, The Lancet. Respiratory medicine.

[25]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[26]  Alvar Agusti,et al.  The COPD control panel: towards personalised medicine in COPD , 2012, Thorax.

[27]  Joan B. Soriano,et al.  Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice , 2012, European Respiratory Journal.

[28]  Richard E. Isaacson,et al.  The Lung Microbiome in Moderate and Severe Chronic Obstructive Pulmonary Disease , 2012, PloS one.

[29]  J. Antó,et al.  Microbiome Diversity in the Bronchial Tracts of Patients with Chronic Obstructive Pulmonary Disease , 2012, Journal of Clinical Microbiology.

[30]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[31]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[32]  Joel Cooper,et al.  The lung tissue microbiome in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[33]  Meilan K. Han,et al.  Significance of the microbiome in obstructive lung disease , 2012, Thorax.

[34]  M. Martínez-García,et al.  Factors associated with bronchiectasis in patients with COPD. , 2011, Chest.

[35]  M. Cosio,et al.  Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. , 2011, American journal of respiratory and critical care medicine.

[36]  B. Celli,et al.  Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation , 2011, European Respiratory Journal.

[37]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[38]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[39]  J. Vestbo,et al.  Current controversies and future perspectives in chronic obstructive pulmonary disease. , 2011, American journal of respiratory and critical care medicine.

[40]  D. Postma,et al.  I have taken my umbrella, so of course it does not rain , 2011, Thorax.

[41]  L. Hood,et al.  Systems medicine and integrated care to combat chronic noncommunicable diseases , 2011, Genome Medicine.

[42]  B. Celli,et al.  Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. , 2011, American journal of respiratory and critical care medicine.

[43]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[44]  I. Pavord,et al.  Acute Exacerbations of COPD: Identification of Biological Clusters and Their Biomarkers , 2011 .

[45]  J. Vestbo,et al.  Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. , 2010, American Journal of Respiratory and Critical Care Medicine.

[46]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[47]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[48]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[49]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[50]  C. Fu,et al.  Study on Mass Customization for Knowledge Production and its Operation Mode , 2009 .

[51]  Vasilis Ntziachristos,et al.  Optical imaging of molecular signatures in pulmonary inflammation. , 2009, Proceedings of the American Thoracic Society.

[52]  David J. Galas,et al.  Systems Biology and Emerging Technologies Will Catalyze the Transition from Reactive Medicine to Predictive, Personalized, Preventive and Participatory (P4) Medicine , 2009 .

[53]  David J. Galas,et al.  Systems Biology and Emerging Technologies Will Catalyze the Transition from Reactive Medicine to Predictive , Personalized , Preventive and Participatory ( P 4 ) Medicine , 2009 .

[54]  T. Taramarcaz,et al.  Broncho-pneumopathie chronique obstructive et infection , 2008 .

[55]  J. Vestbo,et al.  The many "small COPDs": COPD should be an orphan disease. , 2008, Chest.

[56]  A L Hansell,et al.  Proportional classifications of COPD phenotypes , 2008, Thorax.

[57]  A. Agustí.  Chronic Obstructive Pulmonary Disease: Beyond the Forced Expiratory Manoeuvre , 2008, Respiration.

[58]  Damon E. Hyde,et al.  Visualization of pulmonary inflammation using noninvasive fluorescence molecular imaging. , 2008, Journal of applied physiology.

[59]  T. Taramarcaz,et al.  [Chronic obstructive pulmonary disease and infection]. , 2008, Revue medicale suisse.

[60]  K. Rabe,et al.  From COPD to chronic systemic inflammatory syndrome? , 2007, The Lancet.

[61]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[62]  Sanjiv S Gambhir,et al.  Molecular imaging: the vision and opportunity for radiology in the future. , 2007, Radiology.

[63]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[64]  D. Mannino,et al.  Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.

[65]  R. Stockley,et al.  Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype? , 2006, Respiratory research.

[66]  S. Sethi,et al.  Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[67]  I. Pavord,et al.  Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease , 2005, Thorax.

[68]  J. Wedzicha,et al.  Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[69]  T. Murphy,et al.  Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[70]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[71]  C. Sabatti,et al.  The Human Phenome Project , 2003, Nature Genetics.

[72]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[73]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[74]  A. Schols,et al.  Systemic effects in COPD. , 2002, Chest.

[75]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[76]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[77]  R. Stockley,et al.  Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care , 2000, Thorax.

[78]  J. Bousquet,et al.  Global initiative for asthma (GINA) and its objectives. , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[79]  A. Torres,et al.  Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[80]  J. Pijoan,et al.  Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[81]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[82]  Judith Scott Clayton,et al.  The Future , 2001, Nature.